¼¼°èÀÇ Á¤¹Ð ½Å°æº¯¼ºÁúȯ ½ÃÀå(2024-2028³â)
Precision Neurodegenerative Disease Market, Global, 2024-2028
»óǰÄÚµå : 1559498
¸®¼­Ä¡»ç : Frost & Sullivan
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 75 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,450 £Ü 3,416,000
Web Access (Regional License) help
Frost & SullivanÀÇ À¥»çÀÌÆ® ·Î±×ÀÎ ÆÐ½º¿öµå°¡ ¹ßÇàµÇ¸ç, PDF¸¦ ´Ù¿î·Îµå ¹Þ´Â ÇüÅ·ΠÁ¦°øµÉ ¿¹Á¤ÀÔ´Ï´Ù. PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ ¸ðµç ºÐµéÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù


Çѱ۸ñÂ÷

AI ±â´É, Áúº´ º¯Çü Ä¡·á, »ê¾÷ À¶ÇÕÀ¸·Î Á¤¹Ð NDD Ä¡·á´Â Çõ½ÅÀûÀÎ ¼ºÀåÀ» °æÇèÇϰí ÀÖ½À´Ï´Ù.

½Å°æº¯¼ºÁúȯ(NDDs)ÀÇ Àü ¼¼°è À¯º´·ü Áõ°¡·Î ÀÎÇØ ´Ü¹éÁú ¿ÀÆúµù, ½Å°æ ¿°Áõ, ½Ã³À½º ±â´É Àå¾Ö¿Í °°Àº °íÀ¯ÇÑ º´¸®ÇÐÀû ¸ÞÄ¿´ÏÁòÀ» Ç¥ÀûÀ¸·Î ÇÏ´Â ´ëÁõ¿ä¹ý¿¡¼­ Áúº´ º¯Çü Ä¡·á·Î ÀüȯµÇ°í ÀÖÀ¸¸ç, °íÀ¯ÇÑ À¯ÀüÀÚ ÇÁ·ÎÆÄÀÏ, Áúº´ ¾ÆÇü ¹× ¸íÈ®ÇÑ ¹ÙÀÌ¿À¸¶Ä¿¸¦ ±â¹ÝÀ¸·Î ÇÑ ¸ÂÃãÇü Ä¡·á°¡ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. Á¤¹Ð NDD´Â ÀÓ»ó½ÃÇè ¼³°è¿¡ º¯È­¸¦ °¡Á®¿ÔÀ¸¸ç, Á¤¹Ð Áø´Ü¿¡ ±â¹ÝÇÑ ½ÃÇè°ú ÀûÀÀÇü ¼Ò±Ô¸ð ÀÓ»ó½ÃÇè ¼³°è¿¡ µðÁöÅÐ Æ®À©À» »ç¿ëÇÏ°Ô µÇ¾ú½À´Ï´Ù. Á¤¹Ð NDD¿¡ ÁýÁßÇÏ´Â ±â¾÷µéÀº Â÷¼¼´ë ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º, ¿À¹Í½º, ¾à¸®À¯ÀüÇÐÀ» äÅÃÇÏ¿© ¸ÞÄ¿´ÏÁò¿¡ ƯȭµÈ Ä¡·á Á¢±Ù¹ýÀ» °³¹ßÇϰí ÀÖ½À´Ï´Ù. ½Å°æÀ¯Àüü, ¾à¹° ÈļºÀ¯Àüü ¿¬±¸ Ç÷§Æû, »ý¹°Á¤º¸ÇÐ ¼Ö·ç¼Ç°ú °°Àº Á¤¹Ð ¿¬±¸ µµ±¸´Â µ¥ÀÌÅÍ ±â¹Ý ÀÓ»ó ¹× Áß°³¿¬±¸¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. »õ·Î¿î »ý¹°ÇÐÀû ¹ÙÀÌ¿À¸¶Ä¿, µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿, NDD À§ÇèÀ» ¿¹ÃøÇÏ´Â À¯ÀüÀÚ º¯ÀÌüÀÇ ¹ß°ß°ú °ËÁõÀº ȹ±âÀûÀ̸ç, AI, ML, ·Îº¿°øÇÐ, ºòµ¥ÀÌÅÍ ±â¹ÝÀÇ ¸ÖƼ¿À¹Í½º ÅøÀº NDD Ä¡·áÁ¦ ¿¬±¸°³¹ß¿¡ ÀÖ¾î Áß¿äÇÑ °úÁ¦ÀÎ ÀÓ»ó½ÃÇè ½ÇÆÐ¸¦ ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. Ç¥Àû ½Äº°/°ËÁõ Á¤È®µµ¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÈļºÀ¯ÀüÇÐÀû Ä¡·á, ´Éµ¿¸é¿ªÄ¡·á, ´Ü¹éºÐÇØÄ¡·á¿Í °°Àº Ä¡·á Á¢±Ù¹ý°ú ½ÃÄö½Ì µ¿¹ÝÁø´Ü, ½Å°æ¿µ»ó Áø´Ü, ´ÜÀϱ¤ÀÚ¹æ»ç¼±´ÜÃþÃÔ¿µ°ú °°Àº Á¤¹ÐÇÑ ¾ç»óÀÌ Á¤¹Ð NDD¿¡ Àû¿ëµÉ ¿¹Á¤ÀÔ´Ï´Ù. ³ª³ëÀÔÀÚÀÇ ±â¼ú Çõ½ÅÀº Ç÷¾× ³ú À庮À» Åë°úÇÒ ¼ö Àִ ǥÀû ¾à¹°Àü´Þ ¼Ö·ç¼ÇÀ» ¸¸µé¾î³»°í ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â NDD Àü¸Á¿¡¼­ Çõ½ÅÀûÀÎ Ä¡·áÁ¦ ¹× Ç÷§ÆûÀÇ Ã¤ÅÃÀ» Çü¼ºÇÏ´Â µ¿Çâ¿¡ ´ëÇÑ ºÐ¼®À» Æ÷ÇÔÇÏ¿© Àü ¼¼°è Á¤¹Ð NDD »ê¾÷ÀÇ ¹ßÀüÀ» ´Ù·ç°í ÀÖ½À´Ï´Ù. Á¤¹Ð NDD »ê¾÷Àº ½Å¾à °³¹ß ¹× °³¹ß ¼Ö·ç¼Ç, Ç¥Àû Ä¡·áÁ¦, ¸ð´ÏÅ͸µ ¹× ȯÀÚ Áö¿ø ¼Ö·ç¼Ç µî ÀǾàǰ ¹ë·ùüÀÎ Àü¹Ý¿¡ °ÉÄ£ Á¤¹Ð ÀÇ·á(PH) ¾ÖÇø®ÄÉÀ̼ÇÀÇ ÅëÇÕÀ¸·Î ÀÎÇØ º¯È­ÀÇ ½Ã±â¸¦ ¸ÂÀÌÇϰí ÀÖ½À´Ï´Ù. ¾ËÃ÷ÇÏÀÌ¸Ó ¹× ÆÄŲ½¼º´¿¡ ´ëÇÑ ¾÷°è °³¿ä ¹× ÀÓ»ó½ÃÇè ÇöȲ, ÀϹÝÀûÀÎ ±ÔÁ¦ µ¿Çâ, ÁøÈ­ÇÏ´Â Ä¡·á¹ýÀÇ ÇâÈÄ Àü¸Á, PH°¡ ¿Ü°úÀû °³ÀÔ¿¡ ¹ÌÄ¡´Â ¿µÇâ, µðÁöÅÐ-¸ÞµåÅ×Å©-Á¦¾àÀÇ À¶ÇÕ µî ´Ù¾çÇÑ ÀλçÀÌÆ®°¡ Á¦°øµË´Ï´Ù. Çõ½ÅÀûÀÎ ±â¼ú, Ä¡·á¹ý, ¹ÙÀÌ¿À¸¶Ä¿, ¿µ»ó Áø´ÜÀÇ ¹ßÀüÀ» ÅëÇØ ¾ËÃ÷ÇÏÀ̸Ӻ´°ú ÆÄŲ½¼º´ÀÇ °ü¸®¸¦ º¯È­½Ã۰í ÀÖ´Â Çõ½ÅÀû ±â¾÷µé¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. µðÁöÅÐ ¹× ÀÇ·á ±â¼úÀ» »ç¿ëÇÏ¿© Áúº´ÀÇ ÁøÇàÀ» °¨Áö, °ü¸®, ¸ð´ÏÅ͸µÇÏ°í ¸ÂÃãÇü Ä¡·áÁ¦¸¦ Åõ¿©ÇÔÀ¸·Î½á NDD °ü¸®ÀÇ Áß¿äÇÑ °ÝÂ÷¸¦ ÇØ¼ÒÇÒ ¼ö Àֱ⠶§¹®¿¡ Á¦¾à, Áø´Ü ¹× ÀÇ·á±â±â ¾÷ü °£ÀÇ Àü·«Àû ÅëÇÕÀÌ °­Á¶µÇ°í ÀÖ½À´Ï´Ù. ÀÌ Á¶»ç ¼­ºñ½º´Â NDD °ü¸®ÀÇ °ÝÂ÷¸¦ ÇØ¼ÒÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ´Â °¡Àå ³Î¸® º¸±ÞµÈ ºñÁî´Ï½º ¸ðµ¨°ú ½ÅÈï ºñÁî´Ï½º ¸ðµ¨À» ½Äº°Çϰí ÀÖ½À´Ï´Ù. À̸¦ ÅëÇØ ¾÷°è Âü°¡ÀÚµéÀº °æÀï·Â, ¼­ºñ½º Á¦°ø ¹× Áö¸®Àû ¹üÀ§¸¦ °­È­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ½ÃÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ÆÄÆ®³Ê½Ê, ÇöÀç ¹× ¹Ì·¡ µ¿ÇâÀ» ÆÄ¾ÇÇÏ¿© ȯÀÚ Á¢±Ù¼º ºÎÁ· ¹®Á¦¸¦ ÇØ°áÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Àü·«Àû °úÁ¦

¼ºÀå ±âȸ ºÐ¼®

¼ºÀå ȯ°æ

ÀûÀÀÁõ »ç¿ë »ç·Ê - ¾ËÃ÷ÇÏÀ̸Ӻ´

ÀûÀÀÁõ »ç¿ë »ç·Ê - ÆÄŲ½¼º´

¼ºÀå ±âȸ À¯´Ï¹ö½º

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Precision NDD Treatment is Experiencing Transformational Growth due to AI Capabilities, Disease-modifying Therapies, and Industry Convergence

The rising global prevalence of neurodegenerative diseases (NDDs) is driving the shift from symptom-to-disease-modifying therapeutics that target unique pathological mechanisms, such as protein misfolding, neuroinflammation, and synaptic dysfunction, and customizing treatment based on unique genetic profiles, disease subtypes, and distinct biomarkers. Precision NDD has changed clinical trial design, resulting in precision diagnostics-based studies and the use of digital twins for adaptive and small-sized clinical trial designs. Precision NDD-focused companies employ next-generation bioinformatics, omics, and pharmacogenetics to develop mechanism-specific therapy approaches. Precision research tools, such as neural organoids, platforms for pharmacoepigenomics studies, and bioinformatics solutions, enable data-driven clinical and translational research. The discovery and validation of novel biological and digital biomarkers, and genetic variants to predict NDD risk are breakthroughs. AI, ML, robotics, and big data-based multi-omics tools are improving the degree of precision for target identification/validation to limit clinical trial failures, a critical challenge for NDD drug R&D. Therapeutic approaches such as epigenetic therapy, active immunotherapies, protein degradation therapies, and precision modalities, such as sequencing companion diagnostics, neuroimaging, and single photon emission computed tomography, will be adopted for precision NDD. Innovations in nanoparticles are creating game-changing targeted drug delivery solutions that can cross the blood-brain barrier.

Advancements in the global precision NDD industry, including analysis relating to trends shaping the uptake of innovative therapeutics and platforms in the NDD landscape, are covered. The precision NDD industry is undergoing a transformative shift, driven by the integration of precision health (PH) applications across the pharmaceutical value chain, covering drug discovery and development solutions, targeted therapeutics, and monitoring and patient support solutions. Insights include an industry overview and clinical trial landscape of Alzheimer's disease and Parkinson's disease, prevailing regulatory trends, the future outlook of evolving therapeutic modalities, the impact of PH on surgical interventions, and digital-MedTech-Pharma convergence. Insights are provided into game-changing companies developing innovative technologies and treatment modalities, biomarkers, and imaging advancements that are transforming the management of Alzheimer's and Parkinson's diseases. Strategic integration among pharma, diagnostics, and medical device players is highlighted because the convergence of capabilities fills vital gaps in the management of NDDs by enabling the use of digital and MedTech technologies to detect, manage, and monitor disease progression and administer customized therapeutics. The research service identifies the most prevalent and emerging business models that help bridge the gaps in NDD management. This enables industry participants to enhance their competitiveness, service offerings, and geographic outreach. It also addresses the challenges of inadequate patient access by highlighting the primary market drivers, restraints, partnerships, and present and future trends.

Table of Contents

Strategic Imperatives

Growth Opportunity Analysis

Growth Environment

Indication Use Case- Alzheimer's Disease

Indication Use Case- Parkinson's Disease

Growth Opportunity Universe

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â